State Street’s Climb Bio CLYM Stock Holding History

State Street’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.96M	Buy	686,772 +554,772	+420%	+$5.73M	﹤0.01%	2737
2026 Q1	$904K	Buy	132,000 +3,100	+2%	+$17.9K	﹤0.01%	3512
2025 Q4	$516K	Buy	128,900 +25,800	+25%	+$62K	﹤0.01%	3667
2025 Q3	$207K	Hold	103,100	–	–	﹤0.01%	3904
2025 Q2	$128K	Sell	103,100 -275,436	-73%	-$343K	﹤0.01%	3934
2025 Q1	$462K	Hold	378,536	–	–	﹤0.01%	3612
2024 Q4	$681K	Buy	378,536 +63,500	+20%	+$230K	﹤0.01%	3560
2024 Q3	$1.6M	Buy	315,036 +256,029	+434%	+$1.81M	﹤0.01%	3392
2024 Q2	$420K	Buy	59,007 +37,307	+172%	+$248K	﹤0.01%	3596
2024 Q1	$59.5K	Hold	21,700	–	–	﹤0.01%	4128
2023 Q4	$58.2K	Hold	21,700	–	–	﹤0.01%	4169
2023 Q3	$57.3K	Buy	21,700 +1,900	+10%	+$5.18K	﹤0.01%	4252
2023 Q2	$55.4K	Hold	19,800	–	–	﹤0.01%	4393
2023 Q1	$57.4K	Hold	19,800	–	–	﹤0.01%	4471
2022 Q4	$70.9K	Hold	19,800	–	–	﹤0.01%	4466
2022 Q3	$64K	Hold	19,800	–	–	﹤0.01%	4602
2022 Q2	$60K	Sell	19,800 -75,270	-79%	-$356K	﹤0.01%	4688
2022 Q1	$798K	Buy	95,070 +1,991	+2%	+$18.6K	﹤0.01%	3880
2021 Q4	$974K	Buy	93,079 +6,978	+8%	+$104K	﹤0.01%	3820
2021 Q3	$1.55M	Buy	+86,101	New	+$1.78M	﹤0.01%	3682

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's CLYM Position: Q2 2026 in Review

State Street increased its Climb Bio (CLYM) stake by 420% in Q2 2026, buying an estimated $5.73M and bringing the position to 686,772 shares worth $8.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

State Street first reported a position in CLYM in Q3 2021 and has held it in 20 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

State Street held 686,772 shares of Climb Bio worth $8.96M as of Q2 2026.
State Street bought 554,772 Climb Bio shares in Q2 2026, an estimated $5.73M.
Climb Bio made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2737 holding.
State Street first reported a position in Climb Bio in Q3 2021 and has held it in 20 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.